Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603583 | 0.82 | ADORA3 (0.50) | PTGS2KDM4ESMN1; SMN2ADORA3 | |
| SCHEMBL4607588 | 0.74 | KDM4E (0.43) | CHRNA7TRPM8KDM4ESMN1; SMN2ADORA3 | |
| SCHEMBL4606363 | 0.73 | PTGS2 (0.42) | PTGS2KDM4ESCD | |
| SCHEMBL4620856 | 0.73 | SCD (0.41) | PTGS2SCDSLC22A12 | |
| SCHEMBL25422298 | 0.71 | SDHB (0.47) | PTGS2KDM4ESMN1; SMN2SCDSLC22A12 | |
| SCHEMBL23964628 | 0.70 | CHRNA7 (0.54) | CHRNA7TRPM8KDM4ESMN1; SMN2 | |
| SCHEMBL19399180 | 0.70 | CHRNA7 (0.60) | CHRNA7TRPM8KDM4ESMN1; SMN2ADORA3 | |
| SCHEMBL2495357 | 0.70 | ADORA1 (0.48) | PTGS2SCD | |
| SCHEMBL29975679 | 0.69 | SDHB (0.76) | PTGS2KDM4ESMN1; SMN2 | |
| SCHEMBL19805664 | 0.69 | SDHB (0.76) | PTGS2KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1574505-B1 | 1,2,4-THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| CN-100391950-C | 1,2,4-thiadiazole compounds and use thereof | SUMITOMO CHEMICAL CO (JP) | 2008-06-04 | — | — | CN | disclosed |
| US-7361675-B2 | 1,2,4-thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20060167266-A1 | 1,2,4- thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| CN-1688559-A | 1,2,4-thiadiazole compounds and use thereof | SUMITOMO CHEMICAL CO (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1574505-A1 | 1,2,4-THIADIAZOLE COMPOUNDS AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167266-A1 | 1,2,4- thiadiazole compounds and use thereof | CBR3, CBR1, NOX3 | CHRNA7 1039/4885TRPM8 3602/4885PTGS2 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.